Four PARP inhibitors have been approved by regulatory agencies, including Olaparib and Rucaparib in BRCA-mutated ovarian cancer; Niraparib in epithelial ovarian, fallopian tube and primary peritoneal cancer; and Talazoparib in BRCA-mutated breast cancer [44, 45]. This evidence concerns the gene PARP1 and ovarian carcinoma.